Initial Results on Visualization of Coronary Artery Stents at Multiple Heart Rates on a Moving Heart Phantom Using 64-MDCT

Multidetector computed tomography for coronary stents imaging: high-voltage (140-kVp) prospective ECG-triggered versus standard-voltage (120-kVp) retrospective ECG-gated helical scanning

OBJECTIVE

To compare prospective electrocardiogram (ECG)-triggered high-voltage coronary computed tomography (CT) angiography (CTA; 140-kVp P-cCTA) with retrospective ECG-gated standard-voltage cCTA (120-kVp R-cCTA), in patients with coronary stents.

METHODS

Fifty-two patients with coronary stents were studied with 64-slice multidetector scanner. Ninety-three stents were analyzed: 55 with 140-kVp P-cCTA and 38 with 120-kVp R-cCTA. Image quality (IQ), diagnostic confidence (DC), in-stent assessable lumen, artificial narrowing, and effective radiation dose were compared between techniques.

RESULTS

Image quality and DC were significantly better for the 140-kVp P-cCTA in comparison with the 120-kVp R-cCTA (IQ, 1.1 ± 0.36 vs 1.7 ± 0.60, respectively; P < 0.00001. Diagnostic confidence: 1.1 ± 0.29 vs 1.5 ± 0.65 respectively; P < 0.0001). In-stent assessable lumen and artificial narrowing were comparable between the techniques. Effective dose was lower for the 140-kVp P-cCTA (6.7 ± 2.07 mSv vs 15.8 ± 6.89 mSv; P < 0.0001).

CONCLUSIONS

High voltage combined with axial prospective ECG-triggered scan improved IQ and DC in stent cCTA imaging but failed to improve the diameter of in-stent assessable lumen and to reduce the artificial narrowing compared with the 120-kVp R-cCTA. Effective dose was 60% lower for the 140-kVp P-cCTA.

Safety and efficacy of oral ivabradine as a heart rate-reducing agent in patients undergoing CT coronary angiography

OBJECTIVE

To investigate the role of oral ivabradine as a heart rate reducing agent in patients undergoing CT coronary angiography (CTCA). Despite the routine use of β-blockers prior to CTCA studies, it is not uncommon to have patients with heart rates persistently above the target range of 65 bpm. Ivabradine is a selective inhibitor of the I(f) current, which primarily contributes to sinus node pacemaker activity, and has no significant direct cardiovascular effects such as reduction of blood pressure, cardiac contractility or impairment of cardiac conduction.

METHODS

We investigated 100 consecutive patients who had been referred for CTCA for the evaluation of suspected coronary artery disease (CAD). Patients were randomised to receive either of the following two pre-medication protocols: oral metorprolol or oral ivabradine.

RESULTS

Ivabradine was significantly more effective than metorprolol in lowering the heart rate; the mean percentage reduction in heart rate with ivabradine vs metorpolol was 23.89+6.95% vs 15.20+4.50%, respectively (p=0.0001). Metoprolol significantly lowered both systolic and diastolic blood pressure while ivabradine did not. The requirement of additional doses to achieve a target heart rate of <65 beats per min was also significantly more frequent with metoprolol.

CONCLUSION

Ivabradine is a potentially attractive alternative to currently used drugs for reduction of heart rate in patients undergoing CTCA.

CT Imaging of Coronary Stents: Past, Present, and Future

Coronary stenting became a mainstay in coronary revascularization therapy. Despite tremendous advances in therapy, in-stent restenosis (ISR) remains a key problem after coronary stenting. Coronary CT angiography evolved as a valuable tool in the diagnostic workup of patients after coronary revascularization therapy. It has a negative predictive value in the range of 98% for ruling out significant ISR. As CT imaging of coronary stents depends on patient and stent characteristics, patient selection is crucial for success. Ideal candidates have stents with a diameter of 3 mm and more. Nevertheless, even with most recent CT scanners, about 8% of stents are not accessible mostly due to blooming or motion artifacts. While the diagnosis of ISR is currently based on the visual assessment of the stent lumen, functional information on the hemodynamic significance of in-stent stenosis became available with the most recent generation of dual source CT scanners. This paper provides a comprehensive overview on previous developments, current techniques, and clinical evidence for cardiac CT in patients with coronary artery stents.

Coronary artery stent evaluation using a vascular model at 64-detector row CT: comparison between prospective and retrospective ECG-gated axial scans

Objective

We wanted to evaluate the performance of prospective electrocardiogram (ECG)-gated axial scans for assessing coronary stents as compared with retrospective ECG-gated helical scans.

Materials and Methods

As for a vascular model of the coronary artery, a tube of approximately 2.5-mm inner diameter was adopted and as for stents, three (Bx-Velocity, Express2, and Micro Driver) different kinds of stents were inserted into the tube. Both patent and stenotic models of coronary artery were made by instillating different attenuation (396 vs. 79 Hounsfield unit [HU]) of contrast medium within the tube in tube model. The models were scanned with two types of scan methods with a simulated ECG of 60 beats per minute and using display field of views (FOVs) of 9 and 18 cm. We evaluated the in-stent stenosis visually, and we measured the attenuation values and the diameter of the patent stent lumen.

Results

The visualization of the stent lumen of the vascular models was improved with using the prospective ECG-gated axial scans and a 9-cm FOV. The inner diameters of the vascular models were underestimated with mean measurement errors of -1.10 to -1.36 mm. The measurement errors were smaller with using the prospective ECG-gated axial scans (Bx-Velocity and Express2, p < 0.0001; Micro Driver, p = 0.0004) and a 9-cm FOV (all stents: p < 0.0001), as compared with the other conditions, respectively. The luminal attenuation value was overestimated in each condition. For the luminal attenuation measurement, the use of prospective ECG-gated axial scans provided less measurement error compared with the retrospective ECG-gated helical scans (all stents: p < 0.0001), and the use of a 9-cm FOV tended to decrease the measurement error.

Conclusion

The visualization of coronary stents is improved by the use of prospective ECG-gated axial scans and using a small FOV with reduced blooming artifacts and increased spatial resolution.

Safety and efficacy of a rate control protocol for cardiac CT

The clinical application of cardiac CT is increasing, but heart rate control is often required to prevent motion artefact. Here, we describe a protocol for heart rate control in patients undergoing outpatient CT coronary angiography (CTCA). Among 121 consecutive patients, 75 (61.9%) with a resting heart rate >60 beats per minute (bpm) required rate control medication. Our protocol called for oral metoprolol 100 mg to be given 60 min before scanning, with patients for whom beta-blockers were contraindicated receiving 240 mg oral verapamil. Additional 5 mg intravenous boluses (maximum for both drugs, 15 mg) were given if the heart rate remained >60 bpm prior to scanning. Of 71 patients treated with oral metoprolol, 59 (83%) achieved a rate <or=65 bpm and 46 (65%) achieved a heart rate of <or=60 bpm during the CTCA scan. All four patients receiving verapamil had a poor rate response and had heart rates >70 bpm at the time of scanning. No adverse events resulted from rate control medication. Image quality was closely related to heart rate. Severe motion artefact (Grade 3) occurred in only 0.9% of patients with a rate <or=60 bpm compared with 50% of patients with a rate >70 bpm. In conclusion, the administration of oral metoprolol according to the described protocol is a safe and effective way of reducing heart rate and improving scan quality in the majority of patients undergoing CTCA.

The Emerging Role of Multi-Detector Computed Tomography in Heart Failure

BACKGROUND

Recent advances in cardiac multi-detector computed tomography (MDCT) technology now permits entire coronary tree evaluation in a single breath hold with submillimeter slice collimation and improved temporal resolution.

METHODS AND RESULTS

Besides excellent correlation with invasive angiogram for the detection of significant coronary occlusion, MDCT also provides reliable and reproducible data regarding various other cardiac anatomic and functional parameters that are pertinent to heart failure patients. These include left ventricular measurement (eg, ejection fraction, regional wall motion, dimensions, volumes), pulmonary vein anatomy and drainage, right ventricular function, and cardiac venous system, among many others. However, there are radiogenic and nonradiogenic risks associated with MDCT that should be considered before scanning the patients.

CONCLUSIONS

This review summarizes the existing literature of the various cardiac MDCT applications pertinent to heart failure patients.